Development and Validation of a Computational Model for Androgen Receptor Activity.

Paradigms and Technologies
Methods Development


Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more rapidly and inexpensively identify potential androgen-active chemicals. We integrated 11 HTS ToxCast/Tox21 in vitro assays into a computational network model to distinguish true AR pathway activity from technology-specific assay interference. The in vitro HTS assays probed perturbations of the AR pathway at multiple points (receptor binding, coregulator recruitment, gene transcription, and protein production) and multiple cell types. Confirmatory in vitro antagonist assay data and cytotoxicity information were used as additional flags for potential nonspecific activity. Validating such alternative testing strategies requires high-quality reference data. We compiled 158 putative androgen-active and -inactive chemicals from a combination of international test method validation efforts and semiautomated systematic literature reviews. Detailed in vitro assay information and results were compiled into a single database using a standardized ontology. Reference chemical concentrations that activated or inhibited AR pathway activity were identified to establish a range of potencies with reproducible reference chemical results. Comparison with existing Tier 1 AR binding data from the U.S. EPA Endocrine Disruptor Screening Program revealed that the model identified binders at relevant test concentrations (<100 μM) and was more sensitive to antagonist activity. The AR pathway model based on the ToxCast/Tox21 assays had balanced accuracies of 95.2% for agonist (n = 29) and 97.5% for antagonist (n = 28) reference chemicals. Out of 1855 chemicals screened in the AR pathway model, 220 chemicals demonstrated AR agonist or antagonist activity and an additional 174 chemicals were predicted to have potential weak AR pathway activity.


Kleinstreuer, Nicole C; Ceger, Patricia; Watt, Eric D; Martin, Matthew; Houck, Keith; Browne, Patience; Thomas, Russell S; Casey, Warren M; Dix, David J; Allen, David; Sakamuru, Srilatha; Xia, Menghang; Huang, Ruili; Judson, Richard;


  • Androgen Receptor Antagonists/ chemistry
  • Androgen Receptor Antagonists/ metabolism
  • Androgen Receptor Antagonists/ pharmacology
  • Androgens/ chemistry
  • Androgens/ metabolism
  • Androgens/ pharmacology
  • Area Under Curve
  • High-Throughput Screening Assays
  • Humans
  • Models, Theoretical
  • Protein Binding
  • ROC Curve
  • Receptors, Androgen/ chemistry
  • Receptors, Androgen/ genetics
  • Receptors, Androgen/ metabolism
  • Transcriptional Activation/ drug effects

External Links